For early-stage breast cancer patients, genetic markers show whether chemotherapy is likely to have an impact, or if hormone therapy alone is the better option. A new lung cancer drug developed by my company, Novartis, is effective only in patients with non-small-cell lung cancer who have a particular genetic mutation.